COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMA

This work was funded by GSK. Editorial support (in the form of writing assistance, including preparation of the draft letter under the direction and guidance of the authors, collating and incorporating authors’ comments for each draft, and grammatical editing and referencing) was provided by Eva Kane, PhD, at Avalere Health, and was funded by GSK. Mr Martin and Drs Weng, Yang, Kwiatek, and Deb are employees of GSK and hold stocks/shares in GSK. Dr Sullivan has received research funding from GSK.